A placebo effect is the measurable beneficial healing effect that results from the context and meaning of a medical treatment rather than its content. Although orthodox biomedicine has sometimes struggled to reconcile the paradox of seemingly inert medicines producing healing effects, in the placebo studies literature, a number of scholars have proposed that alternative paradigms for understanding perception, such as affordance, motor-intentionality, and enaction, can reconcile the apparent paradigm conflict. These models are by no means incompatible with design theory; in fact, they are both embedded in and enriched by a number of design sub-disciplines, such as user experience design. This article shows that understandings of placebo responsiveness and the effects of meaning and symbol on the body can be identified explicitly or implicitly in existing design and allied practices, including industrial design, graphic and information design, marketing and branding, and architecture.
Although the placebo effect is perhaps not a problem in design, the wider cultural influence of the idea of placebo and what it means affect the contexts in which design's products are encountered. Observing the influence of placebo effects confirms the importance of-and one approach to-articulating and exploring an audience's expectations and understandings of artifacts of meaning and culture. By talking about some of the ways in which the placebo effect has been mobilized in the context of contemporary mid-Atlantic medical and scientific culture, this paper seeks to give a sense of the entangled ontological and epistemological frames that carry influence between disciplines and practicesin particular, the health sciences and the arts. The placebo effect, as it becomes an increasingly influential concept, seems poised to influence how the meaningful aspects of design-its affects and affordances-come to matter. This article proposes that the idea of the placebo response might impact on the way in which design products and practices are received and valued.
The Placebo
To give a "placebo" is to give someone a sham medical treatment in a way that offers the impression that they are receiving something that is "real and effective."
1 Placebo treatments can include inactive "pure" materials, such as sugar pills, or "active" but ineffective treatments, such as below-dose anti-depressants or sham surgery. 2 An essential tool in medical trials, sham treatments are given as controls for the various extraneous factors that cause improvement in subjects. 3 Although the beneficial effects of giving placebos as treatment has been known in medicine for a long time, 4 the practice is still considered somewhat questionable by both patients and physicians. 5 Despite these negative or uncertain perspectives, recent studies suggest that giving ineffective treatments to calm, placate, or even heal patients remains extremely common in general practice in the United Kingdom and United States. 6 In the 1950s, the implication that giving a placebo had healing effects began to receive attention as a thorny problem for evidence-based medicine, demanding a more rigorous approach to medical trials.
7
In recent years, in a shift from considering placebo effects as a risk to evidence-based research, a number of researchers have started to explore their potential uses in medical treatment. Proposals include extending pain medication doses by substituting placebo tablets for the medication, enhancing regular therapeutic encounters through psychological means, or increasing adherence by changing the appearance of medicines.
8
The discourse around the placebo effect offers important insights for the medical humanities because it exposes the epistemological workings of the medical sciences. 9 The methodology of placebo-controlled medical trials separates all possible influences on healing from the treatments being tested, and because of the way in which placebos are so often described as "inert" medicine, the effects that they have seem to be responses to nothing. As a result, some researchers have argued that talking about the placebo response makes more sense-a move that shifts the discussion to focus on how the body-perceiver responds to medical contexts and meanings.
10 Anthropologist Daniel Moerman has pointed out that although placebo effects are by definition limited to the realm of the medical, we should consider the interplay between meaning, symbol and biology in wider cultural contexts, where other phenomena evidence what he calls the "meaning response."
11
According to Moerman, in most contexts, relationships between biology and culture are understood as commonplace; we are rarely Despite this, the discourse around medical testing and certain interpretations of "placebo" as deception and placebo treatments as "inert" stand as both symptom and reinforcement of the separation of cultural and medical realms.
The 1784 Franklin Commission is often held to be the earliest case in which sham treatments were used in a medical trial. Cited by critics and celebrants alike as a key moment in enlightenment medicine, the commission was formed to investigate the healing practices of Viennese physician Franz Anton Mesmer.
13
The goal of the inquiry was to test Mesmer's claim that the effects of his treatments were the result of an objective physical force, known as "animal magnetism."
14 Of the various experiments in the trial, some used deceptive measures. In one example patients were blindfolded and-unaware that the procedure was being carried out-exposed to "mesmeric passes" in which an operator passed his or her hands over the body to influence the flow of the magnetic fluid. The commissioners observed that subjects responded randomly, if at all, to this treatment, which usually had pronounced effects. 15 In another trial, patients were tricked into thinking that a "magnetical operation" was being performed on them from behind a closed door, the deception produced the very same physical responses in the patients as regular mesmeric treatments. 16 In their report, the commissioners concluded that phenomena such as mesmeric "crises," apparently observable in the sometimes theatrical bodily responses of those who experienced Mesmer's treatments, were produced not by animal magnetism, but by actions of "compression" (pressing directly on the body), "imagination," and "imitation" of the well-known behaviors associated with mesmerism. 17 Further, the report argued that the practice was unfit for medical use because the convulsions of the crises had the potential to cause injury to patients.
Isabelle Stengers has argued that this episode marked a point at which the role of the sciences shifted and "scientists took on the role of guardians of an infantile public." 18 She points out that the imagination was a known component of medical practices like mesmerism. The commissioners set the terms of engagement in such a way, according to their report, that mesmerism could not fail to be dismissed as a "frippery." Tangled up with the disputes regarding rationality and materiality were other cultural and political forces-forces intensified by the political turmoil of pre-revolutionary France. In its growing popularity, mesmerism had become associated with revolutionary groups-not least because animal magnetism, although it might sound supernatural to the contemporary ear, was paradoxically Mesmer's attempt to embrace a materialist paradigm. 19 As Stengers points out, "Mesmer's magnetic fluid was taken as a concrete affirmation of human equality, because it put into relation any humans, whatever their class." 20 The result was that the movement interfered both with royalist (and spiritual) hierarchies and with the relationship of scientific medical authority to an apparently irrational and easily misled public.
Expectancy, Affordances, and Affect
The question of what gets to be included within the purview of scientific medicine and what is bracketed remains a concern for contemporary discussions of the placebo effect. Fabrizio Benedetti, a leading placebo researcher in the neurosciences, has cautioned that potential awareness of the discourse might increase public vulnerability to deceptions and quackery. 21 However, legitimizing placebo or meaning effects may have more than epistemological implications.
The past two decades have seen the formation of an interdisciplinary field of placebo studies. Advocates from neuroscience and pharmacology have called for "neuro-bio-behavioural" approaches to understanding placebo effects. 22 They have begun the project of untangling "nonspecific" mechanisms, predominantly by linking them to brain functions, such as the release of certain neurotransmitters and hormones that mediate systems regulating immune function. Although many experimental advances have occurred in the understanding and range of mechanisms that are deemed conduits for information traveling from the realm of the meaningful to that of the physiological, these explanations still tend to be seen as fitting into two main paradigms: conditioning and expectancy. 23 Conditioned responses are understood to be non-cognitive and automatic. 24 Some seemingly impressive placebo responses have been induced in research exploring the modulation of the immune systems of nonhuman animals, such as experimental rats, as well as in human subjects. 25 In experiments of this type, a "learned immune response" is produced by pairing an unconditioned stimuli which lacks a marked physiological effect of its own (e.g., a flavored syrup containing saccharine) with an immune suppressing drug. 26 When the saccharine is later given alone, it produces the same immunosuppressant effects as the drug, without Mesmer was discredited, mesmeric practices persisted partly through the influence of his disciples. Mesmerism (or at least something similar) later re-emerged in the use of hypnosis, in neurology in Saltpetriere, and in medicine in Nancy, and it influenced Freud's development of psychoanalytic techniques. In contrast with the commissioners' dismissal of the imagination, Mesmer's contemporaries were impressed by its effects. In 1800, Englishman John Haygarth undertook experiments with his patients to explore the true value of "metallic tractors"-instruments associated with "perkinsonism," which was an off-shoot of mesmerism, involving the use of the "active" content. 27 In the alternative explanatory model, psychological expectancy results from the manipulations of conscious expectation. In the case of a placebo effect produced by expectancy, the causal agent would be considered to be the positive expectation of healing associated with the medical encounter, context, or placebo treatment. 28 Expectations can be learned from previous experience or can be picked up from social cues or other sources.
Efforts to analyze these two leading views-conditioning and expectancy-quickly show problems. The two accounts appear to interact; it has been shown in experimental work that conditioned responses can be mediated by conscious expectations. 29 These two explanatory models-each insufficient alone, as Oron Frenkel points out-are dogged by the models informing the medical trials that produce them. Both perform and reinforce the tradition of the "separation between mental contents, such as beliefs or expectations, and physiology." 30 Considering placebo effects as either conditioned (bodily and unconscious) or the result of cognitive expectations based on knowledge (conscious or available to consciousness) continues this tendency, failing to address the way in which the discourse constructs placebo effects as impossibilities. However, some researchers have suggested that what is needed is an alternative theory of perception, and that enactivist or existential phenomenological approaches provide this alternative. Frenkel argues that placebo effects might be better understood as the results of the perceived affordances of medical treatment. He suggests an interpretation of James Gibson's concept of perceptual affordance through Maurice Merleau-Ponty's existential phenomenology opens up a way to understand placebo responses as "motor intentional." 31 In this account, activities and objects associated with healing have bodily affordances. Giulio Ongaro and Dave Ward have continued this line of thinking, arguing that the apparent issues are resolved if we situate placebo in an "enactivist" account:
[…] for the enactivist, the parts of an organism, the organism itself, and the environment with which the organism interacts emerge simultaneously from a shared dynamic tangle of processes. It is thus essential to living organisms that they create and sustain their constituent parts and processes, and that their doing so involves a reciprocal causal relationship with their environment. In the enactivist model, cognition is manifested by the environment and physical properties of the organism. By proposing that we adopt a way of thinking that does not separate one from the other, both Frenkel, and Ongaro and Ward clarify that the issue is not a lack of mechanism, but a pervasive habit of categorizing knowledge and experience as separate from the physiological and biological body.
Placebo as Design Deception
The long association of placebo with sham has meant that that the terms placebo and placebo effect have become part of the vernacular, and used to indicate deceptive design tactics, or misconceptions on the part of users. When a New York Times article reported that a large number of the pedestrian crossings in Manhattan had non-functioning buttons, the article's author used the metaphor to describe the perceived effects: "[…] some buttons we regularly rely on to get results are mere artifices-placebos that promote an illusion of control but that in reality do not work."
33 Michael Beirut's article in Design Observer made a similar point about non-functional "close" buttons in elevators, and the signs outside his family home that warned would-be burglars about the (non-functioning) security alarms.
34
In speculative design projects, the term "placebo" has been used loosely to indicate "less defined objects that could invoke desire or imagination,"
35 as well as directly misleading prototype technologies. Anthony Dunne and Fiona Raby's Placebo Project included a non-functioning "electro-draught excluder"-a device that supposedly mopped up electro-magnetic radiation in the home. 36 Like medical placebos, "sham" design interventions invoke responses that offer a way to probe the space of imagination around technological forms and objects. The objects in Dunne and Raby's experiments were both intended to offer "psychological comfort," as well as to open dialogues with participants about how the technologies were incorporated into personal space and narratives. In an echo of mesmerism, one participant reported that the device seemed to modify her perceived physical experience of the electro-magnetic radiation in her home.
37

Form and Medical Efficacy
Some discussions in design have directly invoked the notion of a placebo response as having a healing effect-for example, hospital architecture. 38 In the design of medicines and their packaging, intentionally invoking placebo effects requires care; it raises many side issues-in particular, ethics and patient safety, but also trademarking and intellectual property. The placebo literature shows a range of factors that correlate the appearance and form of medical treatments with their enhanced efficacy. Such factors include the shape and color of tablets and packaging, methods of administering treatment (e.g., injection versus tablet), dosage, adherence to a treatment regimen, information on leaflets and in marketing, and therapeutic rituals and rationales. 39 Despite these apparent opportunities, when working in the delivery of potentially dangerous pharmacological materials, extending imaginative engagement at the potential cost of patient safety, usability and treatment adherence, could naturally appear rather imprudent (i.e., both dangerous and unethical). 40 
Direct-to-Consumer Advertising and the "Irreducible Materiality" of the Trademark
In the United States, where direct-to-consumer advertising (DTCA) of prescription drugs is permitted, the complex effects of presentation become particularly visible. Legal wrangles over "lookalike" generic drugs have raised the question of how design might be biologically "functional." Generic drugs are manufactured by smaller companies that want to offer more competitive prices (and take some of the market share) after larger companies' drug patents have expired. In some cases in which the brand-name drugs are reproduced, the generic tablets and capsules are identical products in drug content, appearance, color, and shape. 41 Although drug patents can be held only for a specific time period, the "trade dress"-the style in which a product is "dressed" for sale (e.g., the iconic black and red of the British Mars Bar or the curved shape of the Coca-Cola bottle) can be protected indefinitely. The argument for protecting against infringements of a product's trade dress are that they may potentially confuse consumers regarding its provenance. Criteria for determining these infringements are centered on the product's appearance and usually exclude any aspects of its function or active content. However, Jeremy Greene cites a number of legal cases regarding generic drugs in which elements that seemed to be trade dress were ruled to be a functional and therapeutic aspect of the medicine. 42 He cites an early precedent: the 1959 court case in which Norwich, the manufacturer of Pepto-Bismol, tried to protect its rights to the pink liquid form in which the product was sold. In a reflection of the studies of the time of color-related placebo effects in gastric physiology and psychosomatic medicine, the court ruled that the "soothing" pink color was a "functional" and "therapeutic" feature of the product and therefore could not be protected as trade dress. 43 Greene suggests that the relationship between presentation and effect seems to be more quickly and easily accepted in contemporary legal contexts. He cites the case of the attention deficit hyperactivity disorder (ADHD) medication Adderall, which has distinctive color and shape schemes-orange and blue tablets and capsules-that correlate to its effects (speed of release) and dosages. In 2003 the Third Circuit Court of Appeals ruled that a generic drug manufacturer should be able to copy the design of the tablets because changing to a generic drug with a different appearance might cause problems for patients. First, it might confuse or mislead consumers about the contents or dosage of the tablets/capsules, but it also might fail to produce the placebo responses that long adherence to the Adderall-branded drug regime would have built up, therefore reducing the effectiveness of the drug. 44 As a mixture of somewhat nonspecific factors, the beneficial "function" of the color and shape includes safety and adherence, as well as the psychological and physiological effects associated with the placebo effect. Color and form might seem relatively basic considerations in the presentation of medicine, but this discussion reveals what Greene calls the "irreducible materiality" of trademarks and trade dress. As he puts it, "[p]harmaceuticals are powerful symbols of reductionism in biomedical therapeutics, but as examination of the lookalike drug controversy reminds us, there is an irreducible materiality to any therapeutics, even within the molecularized and commodified realm of pharmaceuticals." 45 Greene's examples show a mixture of forces at work and suggest changes in attitudes regarding the idea of placebo. Through his account we see how the popular interpretation of scientific medicine is mediated by the legal system and a hardening of probably opportunistic legal precedent, by the complexity and pragmatics of the (supposed) lifeworlds of patients, and by the consumer-focused nature of the U.S. pharmaceutical industry.
In addition to trade dress, marketing itself has received attention for its potential to enhance the effects of prescription drugs through placebo responses. In a 2013 paper titled "Placebogenic Potential Is No Reason to Favour Pharmaceutical Advertising," Paul Biegler responds to the arguments of a 2006 PLOS ONE special issue on pharmaceutical advertising. 46 The opening editorial puts forth the argument that if commercials have conditioning and expectancy effects, they might increase patient response to pharmaceuticals. Therefore, the authors tell us, "it is morally permissible, and perhaps even required, to expose potential drug users to the relevant commercials." 47 In his critique, Biegler accepts that "the placebo response furthers medically desirable outcomes and is, therefore, a warranted treatment component under the guiding principle of beneficence," but he opposes DTCA because the manipulations of response and expectation have the potential to skew "understandings of drug safety and efficacy." 48 His concern is that marketing can cause users of these drugs to develop "unjustified beliefs" regarding their efficacy, preventing them from making "autonomous" choices about their drug regimen. In his 1980 essay, "Advertising, the Magic System," Raymond Williams gives an elegant history of marketing and its growth in early print media and suggests that, in a sense, advertising is "the official art of modern capitalist society." 50 He notes that the earliest controversies around advertising were related to the sale of patent medicines and that by the 1930s, the leading expenditure of advertising revenue as a percentage of sales was in proprietary medicines. 51 We might argue that the underlying nature of medical charlatanry is to exploit peoples' desire to live long lives and to avoid pain and discomfort, but Williams's Marxist analysis also points to the capitalist logic of exploiting all possible potential in a system of production. Here, the productive excess-the "magic" at work-is the bodily affect afforded by advertising. As is clear from the discussions of DTCA and trade dress, this potential, and its connection to placebo effects has not been lost on marketers who have looked at subjective and performance-related responses to the branding of products. 52 In one experiment, the differing effect of recognizable versus unrecognizable brands of isotonic sports drinks on blood pressure regulation were measured. The authors argue that the results showed that participant blood pressure measures reflected the physiological and "subconscious" effects on their bodies exerted by brand expectations.
53 Augmenting and extending the perceived affordances of a product, branding enhances and extends its effects through the action of the perceiver, increasing the value of the product. Imaginative skill and reception-qualities not only attributable to the consumer, but also afforded by their engagement with the material properties of the world-are mobilized to productive effect. That this excess is identified and mobilized within the practices of marketing is no surprise, just as general practitioners make use of placebos in the day-to-day surgeries; in both of these contexts, results rather than epistemic constructs rule the day.
Why Talk About Placebo? Stories About Relations
Placebo responses, and the mechanisms that enable them, remain an ongoing concern in the medical sciences; meanwhile, in design the apparent problems caused by interaction between cognition and physiology seem to present less of a paradox. In design theory, the influence of affordance theory and allied approaches that consider cognition as bodily, active, and situated mean that interactions between expectation and physiology should not seem mysterious. In this case, why talk about the placebo effect, or placebo response?
One suggestion is that the placebo effect's apparent strangeness is useful-primarily because it shows the fault lines between orders of things and where the authority lies to decide what is talked about and what isn't. As Anne Harrington describes in her history of mind-body medicine, The Cure Within, the narratives of mind-body interactions that sound "a bit like biography, a bit like biology, a little like mechanism, a little like meaning" offer a storied world that can "knit together domains of experience that we struggle otherwise to relate." 54 As a cultural object, the placebo effect posits interactions between such categories as emotions, ideas and thoughts, stress, behavior, genes, organ systems, the immune system, and the brain. Generally speaking, the popular science press has used the term "placebo" synonymously with misconception, in a reflection of medical orthodoxy. 55 However, placebo effect narratives make for compelling journalism, and the potential effects of what these stories suggest as they circulate and gather acceptance is worth contemplating. 56 The validation of the placebo effect within popular thought might change the effectiveness of placebos for medical treatments-a possibility suggested by Steve Silberman in a 2009 article for Wired magazine. 57 In addition, such validation also might influence the affordances of meaning: The products of design-images, aesthetics, architecturesmight change or influence somatic or affective experience and in doing so produce knock-on (i.e., indirect) health effects. Even if they are not directly suggestive of this connection, placebo effects, or at least stories about them, still prepare people to experience design in certain ways. The possibility of instrumentalizing the idea of the placebo effect partly then relies on the plausibility of the narratives that explain it, 58 whether they are used to convince a marketing team, a jury, or a patient.
This all suggests a further, if obverse speculation, that a shift in cultural expectations regarding the effects of meaning on the body might change, or in some cases, already have changed the extent to which medical rituals influence healing. Could the absence of such expectations reduce, even eliminate, the effects of meaning-the affective potential of cultural and aesthetic experience? While we should not overlook the inherently affective nature of the meaningful, the evidence associated with the placebo effect reminds us that the ability to perceive, and therefore invoke, the potential for particular outcomes-particularly healing-may be historically and culturally contingent. It is here perhaps, that intervention from design practices is a possibility. 59 As Stengers has pointed out, the tendency to advance "the decided elimination of whatever cannot be connected with a rather vague version of what physicists claim to be reality" enables for the sciences the "conquering of new territories by disqualifying everything that cannot be aligned with what they call 'materialism' or 'naturalism. '" 60 In the contemporary telling of the Franklin Commission's invention of scientific medicine, and the narrow readings of "materialism," the potential of the imagined is collateral in a long-running dispute.
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At a minimum, a discussion of placebo effects can operate so as to shift thinking. Architect Charles Jencks cites Daniel Moerman's work on the placebo effect as a powerful prompt that led him to rethink an accepted truth in architectural practice: that buildings could not be deterministically used to modify their inhabitants. 62 Likewise, the legal and research questions raised in marketing regarding the potential mobilization of placebo effects through marketing, branding, and drug design are symptoms of possible shifts in attitude toward affect and causality. Although the move to theoretical positions that champion accounts of immanence, affect and neo-or vital materialisms pervades the critical humanities, medical humanities, and science and technology studies, the question of how this thinking might be mobilized to shift practice-or perhaps more accurately, our understanding of what is going on in practice-is an ongoing concern.
Summary
The ways of thinking about human perception and experience that inform a number of branches of design practice, such as affordance theory, are not in conflict with the evidence associated with placebo responses and meaning effects. However, "placebo" remains somewhat synonymous with deception and illusion, and reviews of the historical discourses that shape contemporary understandings of the placebo effect suggest that its dismissal might play to disciplinary and cultural imperatives concerned with power and legitimacy. Placebo responses are, to an extent, occult within many design practices that contribute to or are associated with medicine. Examples of the manifestations of the placebo effect in debates around the design of medical treatments suggest that the concept of placebo in the wider culture is both influential and worth attending to. Discussions around DTCA and trade dress acknowledge the placebo effect, but they also support the consequent idea that many aspects of design practice invoke affordances that have implications for healing and might, as in the case of marketing, produce an affective excess. The placebo effect offers a complex example of how the discourses of medical science shape expectations for engagement with the products of design and, as a result, can mediate the affective and somatic potential of cultural products. 
